Gain Therapeutics, Inc. (GANX)
1.79
-0.04
(-2.19%)
USD |
NASDAQ |
Sep 09, 15:07
Gain Therapeutics Net Income (Quarterly) : -4.676M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -4.676M |
| March 31, 2026 | -5.609M |
| December 31, 2025 | -4.538M |
| September 30, 2025 | -5.284M |
| June 30, 2025 | -5.809M |
| March 31, 2025 | -4.530M |
| December 31, 2024 | -3.768M |
| September 30, 2024 | -4.486M |
| June 30, 2024 | -8.143M |
| March 31, 2024 | -4.014M |
| December 31, 2023 | -4.724M |
| September 30, 2023 | -4.718M |
| June 30, 2023 | -7.688M |
| Date | Value |
|---|---|
| March 31, 2023 | -5.137M |
| December 31, 2022 | -4.674M |
| September 30, 2022 | -4.558M |
| June 30, 2022 | -5.085M |
| March 31, 2022 | -3.273M |
| December 31, 2021 | -3.220M |
| September 30, 2021 | -4.664M |
| June 30, 2021 | -3.557M |
| March 31, 2021 | -2.450M |
| December 31, 2020 | -1.656M |
| September 30, 2020 | -0.7944M |
| December 31, 2019 | -0.7096M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 4.676M |
| EPS Diluted (Quarterly) | -0.109 |
| Enterprise Value | 66.84M |
| Earnings Yield | -28.27% |
| Normalized Earnings Yield | -28.27 |